Although other studies allowed the presence of other medications, no clinical trials have been conducted with GH as an adjuvant agent added to homogeneous active treatment in the management of severe and prolonged fibromyalgia with low IGF-1 levels so far. The gene discussed is GH1; the disease is fibromyalgia.